Eurocine and Redbiotec partner to develop HSV-2 vaccines

Eurocine Vaccines and Redbiotec have signed a research and partnership agreement for the development of vaccine candidates against Herpes Simplex Virus Type 2 (HSV-2). Under the agreement, Eurocine will gain exclusive international rights for developing, producing and marketing the vaccines. The vaccines will be developed leveraging some of Redbiotec’s technologies. The agreement comprises both a messenger ribonucleic acid (mRNA) and a protein-based technology within the HSV-2 field. A sexually transmitted disease, HSV-2 is being treated largely with antivirals and there exists currently no effective therapeutic vaccine on the market.

VISCHER is supporting Redbiotec in this partnership with Matthias Staehelin and Christoph Enz (both Corporate).

Matthias Staehelin

Attorney at Law and Civil Law Notary (BS/BL)

• Partner

• +41 58 211 33 53
• [email protected]

Christoph A. Enz

Attorney at Law, Civil Law Notary (BL)

• Associate

• +41 58 211 32 30
• [email protected]